Friday 6 November 2026
Export ADMA’s income statement to Excel — free account
ADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +48.7%
- Free cash flow
- +1,709.5%
- Total debt
- +148.4%
Quarter to September 2026, against a year earlier
12.80
0.41
−3.10%
Follow ADMA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 4 | 5 | 4 |
| 35.56% | 43.30% | 41.90% | 41.95% | ||
| 26.40% | 28.13% | 27.19% | 28.04% | ||
ROIC |
25.69% | 29.70% | 29.78% | 29.48% | |
Return on Tangible Assets |
31.80% | 32.90% | 32.55% | 33.33% | |
Average Days of Receivables |
113.35 | 97.26 | 98.49 | 118.98 | |
Free Cash Flow per Share |
0.12 | 0.48 | 0.51 | 0.59 | |
Free Cash Flow |
27.51 | 112.55 | 116.22 | 132.60 | |
Capital Expenditures |
(22.89) | (15.77) | (20.50) | (8.20) | |
| Other line items | |||||
Cash ROIC |
4.29% | 15.45% | 15.64% | 17.44% | |
Accounts Receivable Turnover |
4.90 | 4.33 | 4.13 | 3.38 | |
Accounts Payable Turnover |
10.17 | 9.60 | 5.88 | 5.48 | |
Inventory Turnover |
1.15 | 1.00 | 0.84 | 0.71 | |
Average Days of Payables |
37.81 | 37.94 | 64.04 | 79.66 | |
Days of Inventory on Hand |
346.63 | 410.57 | 483.11 | 594.46 | |
Tax Rate |
(0.20) | (0.20) | (0.22) | (0.22) | |
Research and Development Expense of Revenue |
0.93% | 1.28% | 2.25% | 2.79% | |
Selling, General and Administrative Expense of Revenue |
17.95% | 18.48% | 19.28% | 19.94% | |
Share Based Compensation of Revenue |
3.93% | 4.26% | 4.47% | 4.63% | |
Interest Coverage |
26.93 | 29.69 | 25.44 | 22.80 | |
Operating CF/Net income |
0.34 | 0.78 | 0.81 | 0.77 | |
Depreciation/Fixed assets |
0.13 | 0.13 | 0.12 | 0.12 | |
Capex/Depreciation |
(2.64) | (1.85) | (2.47) | (1.01) | |
Revenue per Share |
2.14 | 2.16 | 2.24 | 2.32 | |
Operating CF per Share |
0.21 | 0.54 | 0.60 | 0.63 | |
Capex per Share |
(0.10) | (0.07) | (0.09) | (0.04) | |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.02 |
Columns are period end dates · fundamentals updated 6 Nov 2026